| pubmed-article:21391852 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21391852 | lifeskim:mentions | umls-concept:C0024109 | lld:lifeskim |
| pubmed-article:21391852 | lifeskim:mentions | umls-concept:C0027051 | lld:lifeskim |
| pubmed-article:21391852 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:21391852 | lifeskim:mentions | umls-concept:C0005953 | lld:lifeskim |
| pubmed-article:21391852 | lifeskim:mentions | umls-concept:C0162597 | lld:lifeskim |
| pubmed-article:21391852 | lifeskim:mentions | umls-concept:C0013125 | lld:lifeskim |
| pubmed-article:21391852 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
| pubmed-article:21391852 | lifeskim:mentions | umls-concept:C1513143 | lld:lifeskim |
| pubmed-article:21391852 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:21391852 | pubmed:dateCreated | 2011-3-11 | lld:pubmed |
| pubmed-article:21391852 | pubmed:abstractText | Intravenous administration of bone marrow mesenchymal stromal cells (MSCs) is an attractive option for the treatment of myocardial infarction (MI). Previous studies revealed that MSC infusion could limit the deterioration of cardiac function following acute MI; however, little is known regarding the safety and efficacy of MSC infusion for chronic MI. In this study, we address cell retention after intravenous injection in a chronic MI model, and the fate and impact of distributed MSCs in the lung and heart. | lld:pubmed |
| pubmed-article:21391852 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21391852 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21391852 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21391852 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21391852 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21391852 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:21391852 | pubmed:issn | 1746-076X | lld:pubmed |
| pubmed-article:21391852 | pubmed:author | pubmed-author:VighB JBJ | lld:pubmed |
| pubmed-article:21391852 | pubmed:author | pubmed-author:ZhangHaoH | lld:pubmed |
| pubmed-article:21391852 | pubmed:author | pubmed-author:HuShengshouS | lld:pubmed |
| pubmed-article:21391852 | pubmed:author | pubmed-author:QinJiangJ | lld:pubmed |
| pubmed-article:21391852 | pubmed:author | pubmed-author:WeiYingjieY | lld:pubmed |
| pubmed-article:21391852 | pubmed:author | pubmed-author:YuanXinX | lld:pubmed |
| pubmed-article:21391852 | pubmed:author | pubmed-author:JinPeifengP | lld:pubmed |
| pubmed-article:21391852 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21391852 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:21391852 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21391852 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21391852 | pubmed:pagination | 179-90 | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:meshHeading | pubmed-meshheading:21391852... | lld:pubmed |
| pubmed-article:21391852 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21391852 | pubmed:articleTitle | Intravenous administration of bone marrow mesenchymal stromal cells is safe for the lung in a chronic myocardial infarction model. | lld:pubmed |
| pubmed-article:21391852 | pubmed:affiliation | Department of Surgery & Research Center for Cardiac Regenerative Medicine, Cardiovascular Institute & Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. | lld:pubmed |
| pubmed-article:21391852 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21391852 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21391852 | pubmed:publicationType | Evaluation Studies | lld:pubmed |
